Hydroxyapatite Chromatography for ADC Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chromatographic methods for purifying antibody-drug conjugates (ADCs) are inefficient in removing aggregates while maintaining the biological activity of the desired ADC monomers, leading to safety concerns and manufacturing challenges.
Innovation Solution
A hydroxyapatite chromatography method using a sodium phosphate gradient is employed to selectively separate ADC monomers from aggregates, with the elution buffer concentration increasing from 5 to 150 mM, effectively removing aggregates and low molecular weight impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If ion-exchange or hydrophobic interaction chromatography is used to purify ADCs, then purification can be achieved, but aggregates may be induced during purification due to increased protein concentration or buffer changes
Solution Approach 1:
The patent uses a phosphate gradient elution method where the phosphate concentration is gradually increased from low to high concentrations. This gradual parameter change allows for selective elution of monomeric ADCs at lower phosphate concentrations while aggregates remain bound or elute at different concentrations, thereby achieving purification without inducing aggregate formation through abrupt buffer changes.
Solution Approach 2:
The patent introduces phosphate buffer as an intermediary substance that mediates the elution process. The phosphate ions interact with the hydroxyapatite resin to gradually change the binding conditions, allowing selective release of monomers without the harsh conditions that would cause aggregation. The phosphate gradient acts as a gentle mediator between the bound ADCs and the elution buffer.
2Manufacturing precision
If size exclusion chromatography is used to remove aggregates, then aggregate removal can be achieved, but significant dilution of the ADC monomeric product occurs which hinders large-scale manufacturing
Solution Approach 1:
The patent employs a phosphate gradient elution where monomeric ADCs are eluted at specific phosphate concentration ranges that maintain their binding to hydroxyapatite resin. By carefully controlling the gradient profile, the method achieves both aggregate removal and concentration maintenance, as monomers are eluted in a concentrated form rather than being significantly diluted as in size exclusion chromatography.
3Productivity
If harsh elution conditions are used to break tight binding of ADC to matrix, then elution can be achieved, but biological activity of the protein or ADC is destroyed
Solution Approach 1:
The patent uses a gradual phosphate gradient elution method where phosphate concentration is incrementally increased rather than applying harsh conditions abruptly. This gradual parameter change allows for controlled disruption of ADC-matrix binding, achieving efficient elution while maintaining the biological activity of the ADC molecules through gentle, progressive conditions.
4Manufacturing precision
If ion-exchange chromatography is used to separate monomeric and aggregated antibodies, then separation may be achieved, but the isoelectric point differences are too small to allow effective separation
Solution Approach 1:
The patent transitions from ion-exchange chromatography (which relies on isoelectric point differences) to hydroxyapatite chromatography with phosphate gradient elution. This parameter change in the chromatographic mechanism allows separation based on different binding characteristics to hydroxyapatite, where monomeric and aggregated forms exhibit different elution behaviors in the phosphate gradient, overcoming the limitation of small isoelectric point differences.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves a significant reduction in aggregate content to less than 3% and maintains a high percentage of ADC monomers, optimizing the drug-to-antibody ratio and stability of the ADCs for therapeutic applications.
Implementation Method 1
The ADC preparation is loaded onto a hydroxyapatite resin column, washed with a low concentration of sodium phosphate buffer, and eluted through the column with a gradually increasing concentration sodium phosphate buffer; wherein the aggregates are separated from the ADC monomers
Data Source
AI summary
Methods of removing high molecular weight species, in particular aggregates, from antibody drug conjugate preparations, by contacting preparations of the antibody drug conjugate reaction mixture with a hydroxyapatite resin and selectively eluting the ADC from the resin using a gradient comprising sodium phosphate.